Protocol Ledger

NCT03899155 · Phase II · RECRUITING

Pan Tumor Rollover Study

Interventional Phase II clinical trial protocol NCT03899155 sponsored by Bristol Myers Squibb in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-09 Enrollment: 1,500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03899155
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03899155
Protocol FieldVerified Registry Value
NCT IdentifierNCT03899155
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment1,500 participants (ESTIMATED)
Registered Start Date2019-08-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03899155
Hospital Research SiteLocationSite Profile
Dana-Farber Cancer InstituteBoston, MAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI